The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.
about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsmTOR inhibitors in advanced renal cell carcinomamTOR kinase inhibitors as potential cancer therapeutic drugsMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsGene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signalingThe tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptakeEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibPhase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaPhase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaResults of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Enhancing mTOR-targeted cancer therapy.Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway fluxMethylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitorsThe eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translationThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemiaThe combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivoThe phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityChrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.High expression of mTOR is associated with radiation resistance in cervical cancerFirst-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumA phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death.Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.Efficacy and comparative effectiveness of sirolimus as an anticancer drug.Signaling pathways in renal cell carcinoma.Targeting the tumor microenvironment: focus on angiogenesis.The mTOR inhibitor rapamycin suppresses DNA double-strand break repairDual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesThe Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays.Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
P2860
Q21183974-F56AE362-8E63-4A20-87A0-1FCF739DAAD5Q24612127-2DDCFBC2-1A60-4D3D-8E3F-A50EE9910F07Q27027963-CFF2F87E-0B05-48C7-BD8B-2D5424D325FAQ28075606-FB0DDC96-2CF4-4BB5-960F-13BB3C050874Q28299654-791523E7-0C33-4E8A-AE3D-CA2482369A42Q28512637-1D10DC9A-491E-4FAA-842D-9AA432C2DA9AQ28765488-46558519-B3F5-4813-9552-9036D753F0B8Q33383268-EBC58A0B-829E-4B39-912C-2032C74C9750Q33397833-7A2AFBDE-C1B1-4E3D-8CF6-23C266CD1286Q33424649-8B7999E5-A98D-494B-B830-D6C9A1CE6278Q33493174-03F5E4DB-DD1E-4498-A7F5-82C554D22440Q33604979-B24F0CAE-DB0D-469E-A498-4B2A3F5DB091Q33645556-9ABFE747-4C5A-4F2E-B98B-6EDE8F576256Q33655472-0E403DB4-B406-424F-88CD-8F66A1D64DEEQ33702325-91D4F2A7-3935-4EE5-8BA2-B4BF33AD0004Q33762403-B234F110-CC32-40A6-9BD8-4F895245FDA0Q33770769-D3D68B1C-22D6-4041-8B8A-19C888FF077BQ33913826-0507E841-F623-484B-BB9E-96DCCC758059Q33939369-36765AD4-7971-47AC-A959-A0E61A248E75Q34024558-92D7EBA3-C8A2-49B0-AD03-530F6DA49207Q34033097-09BFC623-AA68-4AEC-BF51-05E8E1FFC8DEQ34036041-99F2E25E-77F2-406D-85DC-371349584328Q34150655-B96CC573-202A-4341-8222-CE15CA5333F9Q34167071-137B7D1C-2E1B-47FF-B912-8A8CDC6D39EFQ34183978-563A66FD-7D1B-4E44-8B84-22DD49F38DB2Q34363435-098FA5BD-9BF5-49FF-A8A2-2102BF29C92DQ34452127-42D5E199-FDF4-4F04-9BF0-27D76A2CE1A3Q34658181-3B211775-787B-4ADE-96F9-E19590C913E4Q34767073-90A8C1F3-5A45-4B7F-B87F-BEF627B6F7BBQ34891527-A7C9A018-EDEC-4002-9776-0FEF270DD52CQ34978827-E1C76AF4-E0E5-4CD6-8B84-57946ECA8BCAQ35184806-13269845-B0B1-4626-8F1C-BD4ACA3DFF2EQ35545852-647519DF-713B-4780-BBA8-FBEB8C988C23Q35669226-F9FEF33C-B623-4899-9464-197BF3611665Q35864082-8E8D4C9C-FA1E-4386-ABEF-62FC7070F21FQ36347314-E433A6A8-B73B-459C-8B75-109DE56593A0Q36432654-B8192B8F-B19C-4793-8D2D-98138EF825E8Q36494138-5142A672-3512-4E87-8092-3F0949CA2ABEQ36746834-99055910-362C-4BEC-B878-9557EC332F5DQ36959193-A7305653-E0B0-42A0-AFB9-9974AFA1BB3F
P2860
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The mammalian target of rapamy ...... in the road to cancer therapy.
@en
type
label
The mammalian target of rapamy ...... in the road to cancer therapy.
@en
prefLabel
The mammalian target of rapamy ...... in the road to cancer therapy.
@en
P1476
The mammalian target of rapamy ...... in the road to cancer therapy.
@en
P2093
James J Gibbons
Robert T Abraham
P304
P356
10.1158/1078-0432.CCR-06-2798
P407
P577
2007-06-01T00:00:00Z